Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659631 · ClinicalTrials.gov registry record · Phase 1
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02659631 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT02659631, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.
Interventions
- DRUG PF-06671008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-04-28 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659631
The ClinicalTrials.gov registry entry for NCT02659631 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06671008 is the first listed.
NCT02659631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659631 about?
NCT02659631 is a clinical study titled "PF-06671008 Dose Escalation Study in Advanced Solid Tumors". The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, C...
What is the current status of trial NCT02659631?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-04-28. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT02659631?
The interventions under investigation include: PF-06671008 (DRUG).
Who is sponsoring clinical trial NCT02659631?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.